Sebastian Ewen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1420640/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	13.7	597
2	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.2	189
3	Impact of Lesion Placement on EfficacyÂand Safety of Catheter-Based Radiofrequency Renal Denervation. Journal of the American College of Cardiology, 2015, 66, 1766-1775.	2.8	168
4	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. European Heart Journal, 2016, 38, ehw325.	2.2	104
5	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clinical Research in Cardiology, 2015, 104, 1097-1105.	3.3	76
6	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	2.8	70
7	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. Journal of the American Heart Association, 2017, 6, .	3.7	56
8	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. Clinical Research in Cardiology, 2020, 109, 1500-1506.	3.3	50
9	Drug adherence in patients taking oral anticoagulation therapy. Clinical Research in Cardiology, 2014, 103, 173-182.	3.3	42
10	Response and non-response to renal denervation: who is the ideal candidate?. EuroIntervention, 2013, 9, R54-R57.	3.2	35
11	Effects of Arteriovenous Fistula on Blood Pressure in Patients With Endâ€Stage Renal Disease: A Systematic Metaâ€Analysis. Journal of the American Heart Association, 2019, 8, e011183.	3.7	28
12	Effects of Renal Sympathetic Denervation on Exercise Blood Pressure, Heart Rate, and Capacity in Patients With Resistant Hypertension. Hypertension, 2014, 63, 839-845.	2.7	24
13	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clinical Research in Cardiology, 2020, 109, 845-856.	3.3	24
14	Analyses of drugs stored at home by elderly patients with chronic heart failure. Clinical Research in Cardiology, 2015, 104, 320-327.	3.3	23
15	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. International Journal of Cardiology, 2017, 241, 373-378.	1.7	23
16	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 2016, 18, 672-683.	7.1	21
17	Expert consensus document on the assessment of the severity of aortic valve stenosis by echocardiography to provide diagnostic conclusiveness by standardized verifiable documentation. Clinical Research in Cardiology, 2020, 109, 271-288.	3.3	19
18	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. EuroIntervention, 2018, 14, 121-128.	3.2	19

SEBASTIAN EWEN

#	Article	IF	CITATIONS
19	Hypertension up to date: SPRINT to SPYRAL. Clinical Research in Cardiology, 2017, 106, 475-484.	3.3	18
20	Hypertension: history and development of established and novel treatments. Clinical Research in Cardiology, 2018, 107, 16-29.	3.3	18
21	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. Clinical Research in Cardiology, 2018, 107, 642-652.	3.3	17
22	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2021, 23, 1960-1970.	7.1	14
23	Anatomical and procedural determinants of catheter-based renal denervation. Cardiovascular Revascularization Medicine, 2016, 17, 474-479.	0.8	13
24	Echocardiographic assessment of mitral regurgitation: discussion of practical and methodologic aspects of severity quantification to improve diagnostic conclusiveness. Clinical Research in Cardiology, 2021, 110, 1704-1733.	3.3	12
25	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. Korean Circulation Journal, 2017, 47, 9.	1.9	11
26	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. Cardiovascular Revascularization Medicine, 2018, 19, 845-851.	0.8	11
27	Valvular heart disease in patients with chronic kidney disease. Herz, 2021, 46, 228-233.	1.1	10
28	Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. Journal of Molecular and Cellular Cardiology, 2018, 122, 34-46.	1.9	9
29	The Current Status of Devices for the Treatment of Resistant Hypertension. American Journal of Hypertension, 2020, 33, 10-18.	2.0	9
30	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. Journal of Hypertension, 2016, 34, 2475-2479.	0.5	8
31	Real-time left ventricular pressure–volume loops during percutaneous central arteriovenous anastomosis. European Heart Journal, 2018, 39, 2330-2331.	2.2	8
32	Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension. Current Hypertension Reports, 2014, 16, 430.	3.5	6
33	First-in-human experience: percutaneous renal denervation through a false lumen fenestration in aortic dissection type B. EuroIntervention, 2013, 8, 1110-1110.	3.2	4
34	Long-Term Follow-Up of Baroreflex Activation Therapy in Resistant Hypertension. Hypertension, 2017, 69, 782-784.	2.7	3
35	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. EuroIntervention, 2018, 14, e598-e602.	3.2	3
36	Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. Biomarkers in Medicine, 2016, 10, 841-851.	1.4	2

Sebastian Ewen

#	Article	IF	CITATIONS
37	Renal denervation in patients with heart failure with preserved ejection fraction: end of the beginning?. European Journal of Heart Failure, 2016, 18, 713-715.	7.1	2
38	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a PatientÂWith HOCM. JACC: Case Reports, 2020, 2, 384-388.	0.6	2
39	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. EuroIntervention, 2018, 14, e603-e606.	3.2	2
40	Renal Denervation Induces Reverseâ€Remodeling in Micro <scp>RNA</scp> : Just Blood Pressure Reduction or More?. Journal of Clinical Hypertension, 2016, 18, 495-496.	2.0	0
41	Spontaneous mitral annular rupture. European Heart Journal - Case Reports, 2018, 2, yty097.	0.6	0
42	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Research in Cardiology, 2020, 109, 1507-1509.	3.3	0
43	SARS-CoV-2 vaccination in cardiothoracic organ transplant recipients: effective strategies wanted. Clinical Research in Cardiology, 2021, 110, 1139-1141.	3.3	0
44	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. Herzschrittmachertherapie Und Elektrophysiologie, 2021, , 1.	0.8	0
45	Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization. PLoS ONE, 2022, 17, e0266069.	2.5	0